IDT: Good Medicine
Scott Power
Morgans
IDT: Good Medicine. Under new management IDT is shifting its focus from contract manufacture of pharmaceuticals to more in house development. The acquisition of a portfolio of generic drugs from a global generics company will see IDT capture significantly higher margin than it currently does as a supplier of APIs. The next 18 months will see revenue grow and the business move to profitability. We initiate with an ADD recommendation and a DCF valuation and price target of A$0.37. Full report here: (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media.
I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these sectors, which help with identification of key trends and developments.
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
How to choose excellent fund managers
Livewire Markets
Macro
The RBA should warn that it could raise rates again
Coolabah Capital